5 Eyecare Stocks With Upside Potential

In this piece, we will take a look at the five eyecare stocks with upside potential. For more stocks, head on over to 10 Eyecare Stocks with Upside Potential.

5. National Vision Holdings, Inc. (NYSE:EYE)

Latest Market Capitalization: $1.4 billion

National Vision Holdings, Inc. (NYSE:EYE) is an American company that is headquartered in Duluth, Georgia. The firm makes and sells eyeglasses, contact lenses, other accessories, eye exam products, and more.

National Vision Holdings, Inc. (NYSE:EYE)’s shares trade around $17.5 while its average analyst share price target is $29.64 with a Buy rating. By the end of last year’s fourth quarter, 14 of the 943 hedge funds polled by Insider Monkey had invested in a firm. Out of these, National Vision Holdings, Inc. (NYSE:EYE)’s largest shareholder is Henry Ellenbogen’s Durable Capital Partners which owns 3 million shares that are worth $119 million.

4. Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Latest Market Capitalization: $393 million

Ocular Therapeutix, Inc. (NASDAQ:OCUL) is a biotechnology firm that focuses exclusively on developing eyecare products. Some of these include products that target wound leaks post surgery, and other complications such as post surgery inflammation. The firm is headquartered in Bedford, Massachusetts.

Ocular Therapeutix, Inc. (NASDAQ:OCUL)’s average share price target is $11.86 while its shares currently trade below $5. By the end of Q4 2022, 12 of the 943 hedge funds surveyed by Insider Monkey had invested in the firm. Ocular Therapeutix, Inc. (NASDAQ:OCUL)’s largest investor is James A. Silverman’s Opaleye Management which owns six million shares that are worth $17 million.

3. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Latest Market Capitalization: $86.4 million

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) is a biotechnology firm that is headquartered in Bedford, Massachusetts. It makes and sells treatments for eye diseases.

By the end of December 2022, 15 of the 943 hedge funds polled by Insider Monkey had bought a stake in the company. EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)’s average share price target is $32.33, a massive upside over the current $2.43 share price.

2. OKYO Pharma Limited (NASDAQ:OKYO)

Latest Market Capitalization: $36 million

OKYO Pharma Limited (NASDAQ:OKYO) is a British biotechnology firm that is headquartered in London, the United Kingdom. It develops products for eye inflammation and dry eye diseases. Its leading product is OK-101, which focuses on dry eye diseases, inflammation, and other complications. They are due to start Phase 2 clinical trial in Q2 2023 in Dry Eye Disease with results expected during 2023.

Investment firm Think Equity has a $5 share price target for OKYO Pharma Limited (NASDAQ:OKYO), a significant upside over the current share price of $1.64

1. Kala Pharmaceuticals, Inc. (NASDAQ:KALA)

Latest Market Capitalization: $28 million

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) is an American firm headquartered in Watertown, Massachusetts. It develops treatment for eye defects and post surgery complications.

Four of the 943 hedge funds surveyed by Insider Monkey had bought Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s shares during Q4 2022. Its average share price target of $44.63 is significantly higher than the current share price of $13.97. Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s largest investor in our database is Julian Baker and Felix Baker’s Baker Bros. Advisors which owns 76,813 shares that are worth $2.9 million.

Disclosure: None. The author received no additional compensation for this piece except for what is typically made by Insider Monkey. You can also take a look at 10 Hot Growth Stocks To Buy Now and 13 Best Asian Stocks To Buy Today.

Insider Monkey focuses on uncovering the best investment ideas of hedge funds and investors. Please subscribe to our daily free newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below

Disclosure: No positions. This is a paid sponsored article and is not intended to be investing advice. We don’t guarantee the accuracy of the statements made in this article. Insider Monkey may receive monetary compensation from OKYO Pharma Limited or its agency for publishing this article. Insider Monkey doesn’t recommend purchase/sale of any securities, cryptocurrencies, or ICOs. Please get in touch with a financial professional before making any financial decisions. You understand that Insider Monkey doesn’t accept any responsibility and you will be using the information presented here at your own risk. You acknowledge that this disclaimer is a simplified version of our Terms of Use, and by accessing or using our site, you agree to be bound by all of its terms and conditions. If at any time you find these terms and conditions unacceptable, you must immediately leave the Site and cease all use of the Site.